Connection

DAVID LONARD to Cell Line, Tumor

This is a "connection" page, showing publications DAVID LONARD has written about Cell Line, Tumor.
Connection Strength

0.521
  1. Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironment. Breast Cancer Res. 2022 10 31; 24(1):73.
    View in: PubMed
    Score: 0.071
  2. Development of improved SRC-3 inhibitors as breast cancer therapeutic agents. Endocr Relat Cancer. 2021 08 13; 28(10):657-670.
    View in: PubMed
    Score: 0.066
  3. A genome-scale CRISPR Cas9 dropout screen identifies synthetically lethal targets in SRC-3 inhibited cancer cells. Commun Biol. 2021 03 25; 4(1):399.
    View in: PubMed
    Score: 0.064
  4. SRC-3 transcription-coupled activation, degradation, and the ubiquitin clock: is there enough coactivator to go around in cells? Sci Signal. 2008 Apr 01; 1(13):pe16.
    View in: PubMed
    Score: 0.026
  5. Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma. PLoS One. 2024; 19(4):e0289902.
    View in: PubMed
    Score: 0.020
  6. Lead Compound Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and Anticancer Efficacy. J Med Chem. 2024 Apr 11; 67(7):5333-5350.
    View in: PubMed
    Score: 0.020
  7. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma. Nat Commun. 2021 02 15; 12(1):1022.
    View in: PubMed
    Score: 0.016
  8. The REG? inhibitor NIP30 increases sensitivity to chemotherapy in p53-deficient tumor cells. Nat Commun. 2020 08 06; 11(1):3904.
    View in: PubMed
    Score: 0.015
  9. Steroid receptor coactivator-3 as a target for anaplastic thyroid cancer. Endocr Relat Cancer. 2020 04; 27(4):209-220.
    View in: PubMed
    Score: 0.015
  10. SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma. Cancer Lett. 2019 02 01; 442:310-319.
    View in: PubMed
    Score: 0.014
  11. Proteomic profiling identifies key coactivators utilized by mutant ERa proteins as potential new therapeutic targets. Oncogene. 2018 08; 37(33):4581-4598.
    View in: PubMed
    Score: 0.013
  12. USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells. Nat Commun. 2018 03 28; 9(1):1270.
    View in: PubMed
    Score: 0.013
  13. Targeting SRC Coactivators Blocks the Tumor-Initiating Capacity of Cancer Stem-like Cells. Cancer Res. 2017 08 15; 77(16):4293-4304.
    View in: PubMed
    Score: 0.012
  14. Development of potent small-molecule inhibitors to drug the undruggable steroid receptor coactivator-3. Proc Natl Acad Sci U S A. 2016 May 03; 113(18):4970-5.
    View in: PubMed
    Score: 0.011
  15. HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes. Cancer Res. 2016 Mar 15; 76(6):1463-75.
    View in: PubMed
    Score: 0.011
  16. Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug. PLoS One. 2015; 10(10):e0140011.
    View in: PubMed
    Score: 0.011
  17. Characterization of a Steroid Receptor Coactivator Small Molecule Stimulator that Overstimulates Cancer Cells and Leads to Cell Stress and Death. Cancer Cell. 2015 Aug 10; 28(2):240-52.
    View in: PubMed
    Score: 0.011
  18. Tamoxifen inhibits ER-negative breast cancer cell invasion and metastasis by accelerating Twist1 degradation. Int J Biol Sci. 2015; 11(5):618-28.
    View in: PubMed
    Score: 0.011
  19. Steroid receptor coactivator 1 is an integrator of glucose and NAD+/NADH homeostasis. Mol Endocrinol. 2014 Mar; 28(3):395-405.
    View in: PubMed
    Score: 0.010
  20. Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res. 2014 Mar 01; 74(5):1506-1517.
    View in: PubMed
    Score: 0.010
  21. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A. 2013 Apr 23; 110(17):6997-7002.
    View in: PubMed
    Score: 0.009
  22. SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization. Genes Dev. 2013 Feb 01; 27(3):274-87.
    View in: PubMed
    Score: 0.009
  23. ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. J Clin Invest. 2012 May; 122(5):1869-80.
    View in: PubMed
    Score: 0.009
  24. Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1. Mol Endocrinol. 2011 Dec; 25(12):2041-53.
    View in: PubMed
    Score: 0.008
  25. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene. 2011 Oct 20; 30(42):4350-64.
    View in: PubMed
    Score: 0.008
  26. REGgamma modulates p53 activity by regulating its cellular localization. J Cell Sci. 2010 Dec 01; 123(Pt 23):4076-84.
    View in: PubMed
    Score: 0.008
  27. OTU Domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) deubiquitinates estrogen receptor (ER) alpha and affects ERalpha transcriptional activity. J Biol Chem. 2009 Jun 12; 284(24):16135-16145.
    View in: PubMed
    Score: 0.007
  28. A repressive role for prohibitin in estrogen signaling. Mol Endocrinol. 2008 Feb; 22(2):344-60.
    View in: PubMed
    Score: 0.006
  29. SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock. Cell. 2007 Jun 15; 129(6):1125-40.
    View in: PubMed
    Score: 0.006
  30. The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. Cell. 2006 Jan 27; 124(2):381-92.
    View in: PubMed
    Score: 0.006
  31. Inhibition of the 26S proteasome blocks progesterone receptor-dependent transcription through failed recruitment of RNA polymerase II. J Steroid Biochem Mol Biol. 2005 Mar; 94(4):337-46.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.